As the first gene therapies approach the market, drug makers, insurers, and patients are debating complex questions about cost, value, and payment plans.
By Meghana Keshavan, STAT
Support Provided By: Learn more
Educate your inbox
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.